The Effect of Topical Adriamycin in Superficial Bladder Tumors: A 5-Year Follow-up
Two hundred and forty patients with superficial bladder carcinoma were treated in the Department of Urology of Marburg University between 1979 and 1984. Patients with primary tumors had transurethral resection (TUR) alone, whereas patients with at least two recurrences in their prior history received doxorubicin (Adriamycin, Farmitalia; ADM) as recurrence prophylaxis in addition to TUR. In the case of further recurrence without muscle invasion, local treatment with ADM was repeated for patients in the ADM group and was offered to patients in the TUR alone group. The results presented in the following refer to patients who received either TUR plus ADM or repeated TUR alone, without a topical recurrence prophylaxis.
KeywordsTumor Progression Superficial Bladder Cancer Muscle Invasion Superficial Bladder Tumor Prevent Tumor Recurrence
Unable to display preview. Download preview PDF.